JOP20210087A1 - طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين - Google Patents

طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين

Info

Publication number
JOP20210087A1
JOP20210087A1 JOP/2021/0087A JOP20210087A JOP20210087A1 JO P20210087 A1 JOP20210087 A1 JO P20210087A1 JO P20210087 A JOP20210087 A JO P20210087A JO P20210087 A1 JOP20210087 A1 JO P20210087A1
Authority
JO
Jordan
Prior art keywords
dapagliflozin
methods
kidney disease
chronic kidney
treating chronic
Prior art date
Application number
JOP/2021/0087A
Other languages
English (en)
Inventor
Maria Langkilde Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority claimed from PCT/EP2021/058727 external-priority patent/WO2022022865A1/en
Publication of JOP20210087A1 publication Critical patent/JOP20210087A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتوجه الكشف الحالي إلى طرق علاج مرضى يعانون من مرض الكلى المزمن (CKD)، مع أو بدون مرض السكري من النوع 2، باستخدام مثبط SGLT2، مثل داباغليفلوزين.
JOP/2021/0087A 2020-07-27 2021-04-01 طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين JOP20210087A1 (ar)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063057139P 2020-07-27 2020-07-27
US202063070869P 2020-08-27 2020-08-27
US202063082524P 2020-09-24 2020-09-24
US202063093961P 2020-10-20 2020-10-20
US202063119711P 2020-12-01 2020-12-01
US202163152445P 2021-02-23 2021-02-23
US202163161629P 2021-03-16 2021-03-16
PCT/EP2021/058727 WO2022022865A1 (en) 2020-07-27 2021-04-01 Methods of treating chronic kidney disease with dapagliflozin

Publications (1)

Publication Number Publication Date
JOP20210087A1 true JOP20210087A1 (ar) 2023-01-30

Family

ID=79551924

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0087A JOP20210087A1 (ar) 2020-07-27 2021-04-01 طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين

Country Status (13)

Country Link
EP (1) EP4188389A1 (ar)
JP (1) JP2023536009A (ar)
KR (2) KR20220097854A (ar)
CN (3) CN116392472A (ar)
AU (2) AU2021202643B2 (ar)
BR (1) BR112021008094A2 (ar)
CA (1) CA3116533A1 (ar)
CR (1) CR20210222A (ar)
DO (1) DOP2021000083A (ar)
IL (2) IL311682A (ar)
JO (1) JOP20210087A1 (ar)
MX (1) MX2021005191A (ar)
PE (1) PE20231306A1 (ar)

Also Published As

Publication number Publication date
IL282665A (en) 2021-12-01
KR20230149329A (ko) 2023-10-26
AU2021202643A1 (en) 2022-02-10
BR112021008094A2 (pt) 2022-02-22
CN116392472A (zh) 2023-07-07
CN114209689B (zh) 2023-02-17
KR20220097854A (ko) 2022-07-08
CN114209689A (zh) 2022-03-22
CN114630682A (zh) 2022-06-14
MX2021005191A (es) 2022-04-18
DOP2021000083A (es) 2022-04-18
AU2023202490A1 (en) 2023-05-11
EP4188389A1 (en) 2023-06-07
CR20210222A (es) 2022-08-29
JP2023536009A (ja) 2023-08-23
PE20231306A1 (es) 2023-08-24
AU2021202643B2 (en) 2023-02-02
CA3116533A1 (en) 2022-01-27
IL311682A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2021000295A (es) Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon.
WO2007070637A3 (en) Method of treating open wounds using hypochlorous acid
MX2022001004A (es) Inhibidores de enzimas.
ATE445406T1 (de) Verwendung von eisen(iii)-komplexverbindungen
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
WO2022119858A8 (en) Compounds for the treatment of sars
MX2021005191A (es) Metodos de tratamiento de enfermedad renal cronica con dapagliflozina.
UY39156A (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
DE60331254D1 (de) Nahrungsmittelverarbeitung mittels schockwellen
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
MX2022005376A (es) Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
MX2022002683A (es) Metodo terapeutico o profilactico para diabetes usando medicamentos combinados.
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
AR121738A1 (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
WO2022216379A8 (en) Combination therapies for the treatment of cancer
WO2022119854A8 (en) Compounds for the treatment of sars
JOP20220073A1 (ar) استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية